[Immunological and metabolic disorders and the means for their correction in patients with chronic bronchitis].
A study was made of certain immunity characteristics and of the activity of lipid peroxidation (LPO) in patients of two groups with frequent exacerbations of chronic bronchitis in the phase of lingering exacerbation. The patients of one of the groups received intravenous infusions of piracetam (30 mg/kg bw, 10-12 injections per course) in addition to the common therapy; the other group patients were administered aminalon (1.5-3 g/day for 18-20 days). Activation of LPO was found to be associated with inhibition of the T cell component of the immune system, since cell metabolites exerted a toxic action on lymphocytes. Piracetam and aminalon not only produce the beneficial clinical effects but also favour immunity normalization due to the regulative influence on LPO as well as via the hypothalamo-hypophyseo-adrenal system.
Sil'vestrov
V P
VP
Kinitin
A V
AV
Chesnokova
I V
IV
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D000975:Antioxidants; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010889:Piracetam / Q000627:therapeutic use; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000975:Antioxidants; D005680:gamma-Aminobutyric Acid; D010889:Piracetam
Ob immunologicheskikh i metabolicheskikh narusheniiakh i putiakh ikh korrektsii u bol'nykh khronicheskim bronkhitom.